Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 14/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24009522 | 0.79 | PDE10A (0.55) | PDE10ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2209746 | 0.78 | PDE10A (0.50) | PDE10ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL29589019 | 0.78 | PDE10A (0.56) | PDE10ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL31467684 | 0.78 | PDE10A (0.50) | PDE10ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL5245231 | 0.78 | PDE10A (0.56) | PDE10ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2206398 | 0.78 | PDE10A (0.54) | PDE10ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL31467708 | 0.78 | PDPK1 (0.51) | — | |
| Hydrochloric Acid SCHEMBL6097190 | 0.76 | PDE10A (0.55) | PDE10ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL24838546 | 0.75 | PDE10A (0.49) | PDE10A | |
| SCHEMBL4436437 | 0.73 | PDE10A (0.48) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802585-A1 | 4-SUBSTITUTED 4,6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS | Memory Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | claimed |
| US-20060160814-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-20 | — | — | US | claimed |
| WO-2006028957-A1 | 4-SUBSTITUTED 4, 6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-03-16 | — | — | WO | claimed |
| EP-1802585-A1 | 4-SUBSTITUTED 4,6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS | Memory Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20060160814-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-20 | — | — | US | disclosed |
| WO-2006028957-A1 | 4-SUBSTITUTED 4, 6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160814-A1 | Phosphodiesterase 10 inhibitors | PDE5A, PDE3A, PDE2A | PDE10A 8/4885SLC2A1 4187/4885CYP1A2 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.